6.08
price up icon0.50%   0.03
after-market After Hours: 6.08
loading
Tenax Therapeutics Inc stock is traded at $6.08, with a volume of 6,579. It is up +0.50% in the last 24 hours and up +5.46% over the past month. Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
See More
Previous Close:
$6.05
Open:
$6.26
24h Volume:
6,579
Relative Volume:
0.29
Market Cap:
$25.23M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.3615
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
+0.52%
1M Performance:
+5.46%
6M Performance:
+6.29%
1Y Performance:
+75.72%
1-Day Range:
Value
$6.03
$6.26
1-Week Range:
Value
$6.03
$6.3109
52-Week Range:
Value
$2.77
$7.89

Tenax Therapeutics Inc Stock (TENX) Company Profile

Name
Name
Tenax Therapeutics Inc
Name
Phone
919-855-2100
Name
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Name
Employee
6
Name
Twitter
@TenaxThera
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
TENX's Discussions on Twitter

Compare TENX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TENX
Tenax Therapeutics Inc
6.08 25.10M 0 -14.56M -12.46M -16.82
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-24-24 Initiated Leerink Partners Outperform
Oct-14-24 Initiated Guggenheim Buy
Sep-30-24 Initiated William Blair Outperform
May-18-17 Upgrade Ladenburg Thalmann Neutral → Buy
Dec-16-14 Initiated MLV & Co Buy
Nov-18-14 Initiated WallachBeth Buy
View All

Tenax Therapeutics Inc Stock (TENX) Latest News

pulisher
May 29, 2025

Where are the Opportunities in (TENX) - news.stocktradersdaily.com

May 29, 2025
pulisher
May 23, 2025

Tectonic, Tenax, others aim for shift in heart failure - BioWorld MedTech

May 23, 2025
pulisher
May 20, 2025

Tenax Therapeutics Reports Increased Losses Amid Strategic Investments - TipRanks

May 20, 2025
pulisher
May 19, 2025

William Blair Cuts Earnings Estimates for Tenax Therapeutics - Defense World

May 19, 2025
pulisher
May 19, 2025

Leerink Partnrs Brokers Boost Earnings Estimates for TENX - Defense World

May 19, 2025
pulisher
May 19, 2025

Roth Capital Issues Negative Forecast for TENX Earnings - Defense World

May 19, 2025
pulisher
May 18, 2025

(TENX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 18, 2025
pulisher
May 18, 2025

What is William Blair’s Estimate for TENX FY2028 Earnings? - Defense World

May 18, 2025
pulisher
May 18, 2025

Roth Capital Has Bearish Forecast for TENX FY2028 Earnings - Defense World

May 18, 2025
pulisher
May 16, 2025

Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com - Defense World

May 16, 2025
pulisher
May 16, 2025

Tenax Therapeutics: Q1 Earnings Snapshot - Bluefield Daily Telegraph

May 16, 2025
pulisher
May 16, 2025

Tenax Therapeutics (TENX) Projects Funding Through 2027 | TENX S - GuruFocus

May 16, 2025
pulisher
May 15, 2025

Analyst Adjusts Tenax Therapeutics (TENX) Price Target, Maintains Buy Rating | TENX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Tenax Therapeutics (TENX) Advances Phase 3 Studies in 2025 | TEN - GuruFocus

May 15, 2025
pulisher
May 14, 2025

Tenax Therapeutics Inc Reports Q1 2025 Net Loss of $10.4 Million Amid Rising R&D and Administrative Expenses - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tenax Therapeutics (TENX) Projects Funding Through 2027 | TENX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Tenax Advances Breakthrough PH-HFpEF Treatment: Phase 3 Trial Updates and $111M War Chest Revealed - Stock Titan

May 14, 2025
pulisher
May 11, 2025

Tenax Therapeutics (TENX) Projected to Post Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 08, 2025

(TENX) Technical Data - news.stocktradersdaily.com

May 08, 2025
pulisher
May 08, 2025

Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated by Analysts at StockNews.com - Defense World

May 08, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Boosts Stock Position in Tenax Therapeutics, Inc. (NASDAQ:TENX) - Defense World

May 05, 2025
pulisher
May 02, 2025

Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated at StockNews.com - Defense World

May 02, 2025
pulisher
Apr 25, 2025

Form SC 13G/AStatement of Beneficial Ownership by Certain Investors: [Amend] - ADVFN

Apr 25, 2025
pulisher
Apr 25, 2025

SEC Form DEF 14A filed by Tenax Therapeutics Inc. - Quantisnow

Apr 25, 2025
pulisher
Apr 25, 2025

Form DEF 14A TENAX THERAPEUTICS, INC. For: Apr 24 - StreetInsider

Apr 25, 2025
pulisher
Apr 24, 2025

Tenax Therapeutics Advances Cardiopulmonary Therapies - TipRanks

Apr 24, 2025
pulisher
Apr 22, 2025

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - The Globe and Mail

Apr 22, 2025
pulisher
Apr 21, 2025

Oxygen Biotherapeutics, Inc. : Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast - marketscreener.com

Apr 21, 2025
pulisher
Apr 17, 2025

Teanx Therapeutics plans secondary offering - MSN

Apr 17, 2025
pulisher
Apr 16, 2025

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

Tenax Therapeutics (TENX) Files Prospectus for Stock Resale - GuruFocus

Apr 16, 2025
pulisher
Mar 31, 2025

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Exclusive: Tenax Leadership Team to Unveil Latest Phase 3 Progress at Major Healthcare Conference - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

What is Leerink Partnrs’ Forecast for TENX Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Equities Analysts Offer Predictions for TENX Q1 Earnings - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Q1 Earnings Estimate for TENX Issued By William Blair - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Research Analysts Set Expectations for TENX Q1 Earnings - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

When (TENX) Moves Investors should Listen - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Tenax Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tenax Therapeutics: Q4 Earnings Snapshot - CT Insider

Mar 25, 2025

Tenax Therapeutics Inc Stock (TENX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Cap:     |  Volume (24h):